Jade Biosciences Inc JBIO

$13.41 -0.66 (-4.69%)

Valuation

Market cap
894,810,000
Revenue TTM
$0
Net income TTM
$-127,410,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
493,800
Avg volume
870,136
Day's range
$13.15 – $14.34
Shares out
63,597,000
Stochastic %K
13%
Beta
1.64
Analysts
Strong Sell
Price target
$49.89

Price

Company profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc....

Show more

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
781 312 3013
Website
https://jadebiosciences.com
Address
Building 23, Suite 105 221 Crescent Street, Waltham, United States

Latest news

Stocktwits

Quantumup Oct 1, 11:59 AM
Wedbush reiterated $JBIO Outperform-$47 after the Co. reported preliminary preclinical data for JADE301 at EADV and remained on track to kick off a Phase 1 healthy volunteer study in 4Q26. $PFE $ROIV AZN ARGX OTSKY TVTX VERA VRTX NVS Wedbush said in its note: Preclinical JADE301 data demonstrates ~3x longer half-life vs. dazukibart (PFE, not covered). Additionally, the JADE301 SC and IV doses demonstrated similar time/concentration profiles. Phase 1 results will better inform on human dosing and safety. Bottom line, we see the initial data appearing supportive. No change to our JBIO estimates as we continue to leave JADE301 as upside to our estimates. We look ahead to 2027 as an important turning point for JBIO with multiple readouts lining up including initial JUNIPER Phase 2 JADE101 data.
0 replies
Quantumup Sep 30, 7:54 PM
Stifel on $JBIO (Buy; $40): We're reiterating our Buy rating on JBIO following preclinical updates presented at EADV for recently-disclosed JADE301, a half-life extended anti-IFN-ẞ mAb for Dermatomyositis. $PFE $ROIV AZN ARGX OTSKY TVTX VERA ARWR NVS BIIB - RHHBY AMGN Here's what else Stifel had to say in its note to investors: https://x.com/Quantumup1/status/2105385653227721151?s=20
0 replies
Quantumup Sep 8, 11:54 AM
Oppenheimer⬆️ $CLYM's PT to $25, stays Outperform and said -- The recent CLYM116 reveal illustrates a best-in-class clinical profile for IgAN as echoed by our KOL discussion. $JBIO $OTSKY VERA TVTX NVS VRTX TAK IONS ALNY - REGN SNY AMGN UCBJY H.C. Wainwright⬆️ Climb Bio's PT to $30 and reiterated Buy. Here's what Oppenheimer went on to say and what H.C. Wainwright said in their notes to investors: https://x.com/Quantumup1/status/2097292170218586505?s=20
0 replies
Quantumup Sep 4, 1:06 PM
Piper Sandler⬆️ $CLYM's PT to $40 from $23, reit'd Overweight and said that CLYM116 data surpassed expectations—validated a best-in-class product profile. $JBIO $OTSKY VERA TVTX NVS VRTX TAK IONS ALNY -REGN SNY AMGN UCBJY BRiley⬆️ Climb Bio's PT to $30 from $26, reit'd Buy and said that CLYM116 data landed at our base case—the sweeper mechanism differentiation for CLYM116 showed where it matters.
0 replies
Quantumup Sep 3, 6:48 PM
BTIG⬆️ $CLYM's PT to $32, keeps at Buy and said that it believes CLYM116 could have cont'd success in IgAN—points to exceedingly large comm opp—est'd at $20B+ in the US alone. $OTSKY $JBIO VERA TVTX NVS VRTX TAK IONS ALNY REGN SNY AMGN UCBJY Here's what BTIG said in its note: https://x.com/Quantumup1/status/2095584363664507127?s=20
0 replies
Quantumup Sep 3, 4:40 PM
Baird⬆️ $CLYM's PT to $25 from $21, keeps at Outperform and said -- Raising target on differentiated PK/PD data. $JBIO $VERA TVTX OTSKY NVS VRTX TAK IONS ALNY - REGN Baird added—The Ph1 data for CLYM116 are encouraging, with near-complete APRIL suppression and impressive reductions in IgA and Gd-IgA1 in healthy volunteers. We think this suggests a profile that is likely similar to earlier-gen anti-APRILs but with a substantially longer half life. With initial Ph2 data 1H27 and a planned 2027 Ph3 initiation, we see a nice pacing of data for the program. We're raising our probability of success to 50% on the proof of concept, bringing our price target to $25/shr.
0 replies
Doozio Aug 19, 12:55 AM
$JBIO n it’s still early if no fatch 💣 lands.
0 replies
Quantumup Aug 12, 3:42 PM
BTIG Sees Positive Readthroughs to $JBIO (Buy-$77), $ORKA (Buy-$151), $SYRE (Buy-$132), CBIO (NR), and DMRA (NR) after ABBV (NR) & APGE (⬇️to Neutral) M&A. *Notes APGE as the First Successful Partnered Exit from Paragon Labs/Fairmount of the Group Mentioned Above. Here's what BTIG said in its note to investors: https://x.com/Quantumup1/status/2087565029822320875?s=20
0 replies